Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 19

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Chinese Herbal Medicine for Irritable Bowel Syndrome: A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials

Zheng, Hui, Jin, Song, Shen, Yin-Li, Peng, Wen-Yan, Ye, Kun, Tang, Tai-Chun, Zhao, Jun, Chen, Min, Li, Zhi-Gang·2021·Frontiers in Pharmacology
DOI 10.3389/fphar.2021.694741
Open this paper in CoChat — free account

Abstract

Purpose: Chinese herbal medicine (CHM) is an important complementary and alternative therapy for the management of irritable bowel syndrome (IBS). Previous meta-analyses suggested that CHM is effective for IBS; nonetheless, its effectiveness is inconclusive owing to repeated significance testing. We aimed to examine the efficacy and safety of CHM for IBS through a meta-analysis and trial sequential analysis (TSA). Methods: We searched OVID Medline, Embase, Cochrane Central Register of Controlled Trials, and Web of Science from January 1, 1980, to September 20, 2020. The primary outcome was adequate relief of global IBS symptoms. The secondary outcomes included relief of abdominal pain and treatment-related adverse events. The relative ratio (RR) and required information size (RIS) were calculated for each outcome. Results: Ten trials recruiting 2,501 participants were included. Seven (70%) trials were at low risk of bias (RoB). Compared with placebo, CHM was associated with a significantly higher proportion of adequate relief of global IBS symptoms [RR 1.76 (95% confidence interval (95%CI), 1.33–2.33); I 2 = 81.1%; p < 0.001]. The RIS was 1,083 for the primary outcome, and the accrued information size was 1,716. The analysis of the relief of abdominal pain (three trials with 916 participants) showed similar results compared with placebo [RR 1.85 (95%CI, 1.59–2.14); I 2 = 0%; p < 0.001; RIS = 197 participants]. CHM was associated with a higher proportion of adverse events compared with placebo [RR 1.51 (95%CI, 1.14–2); I 2 = 0%; p = 0.004]. Conclusion: CHM was effective in relieving IBS symptoms but caused a higher adverse event rate than placebo. TSA analysis confirmed the findings with sufficient information size.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2021.694741

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 44

  1. Bahrami, 2016, Herbal Medicines for the Management of Irritable Bowel Syndrome: A Systematic Review, Electron. Physician, 8, 2719, 10.19082/2719 · DOI
  2. Bensoussan, 2015, Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-Predominant Irritable Bowel Syndrome: A Randomized Controlled Trial, Clin. Gastroenterol. Hepatol., 13, 1946, 10.1016/j.cgh.2015.06.022 · DOI
  3. Bensoussan, 1998, Treatment of Irritable Bowel Syndrome with Chinese Herbal Medicine, JAMA, 280, 1585, 10.1001/jama.280.18.1585 · DOI · Paper page
  4. Bian, 2006, Effectiveness of the Chinese Herbal Formula TongXieYaoFang for Irritable Bowel Syndrome: a Systematic Review, J. Altern. Complement. Med., 12, 401, 10.1089/acm.2006.12.401 · DOI
  5. Black, 2020, Global burden of Irritable Bowel Syndrome: Trends, Predictions and Risk Factors, Nat. Rev. Gastroenterol. Hepatol., 17, 473, 10.1038/s41575-020-0286-8 · DOI
  6. Borm, 2009, Updating Meta-Analyses Leads to Larger Type I Errors Than Publication Bias, J. Clin. Epidemiol., 62, 825, 10.1016/j.jclinepi.2008.08.010 · DOI
  7. Carrasco-Labra, 2019, AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D), Gastroenterology, 157, 859, 10.1053/j.gastro.2019.06.014 · DOI · Paper page
  8. Chang, 2016, Effects of Baseline Abdominal Pain and Bloating on Response to Lubiprostone in Patients with Irritable Bowel Syndrome with Constipation, Aliment. Pharmacol. Ther., 44, 1114, 10.1111/apt.13807 · DOI
  9. Chen, 2017, Tongxie Yaofang Regulates Expression of BDNFmRNA in IBS-D Rats to Ease Visceral Hypersensitivity: a Mechanism Study [article in Chinese], Chin. Arch. Traditional Chin. Med., 35, 3095
  10. Chen, 2020, Pharmacologic Treatments for Irritable Bowel Syndrome: an Umbrella Systematic Review, J. Gastrointestin. Liver. Dis., 29, 199, 10.15403/jgld-817 · DOI
  11. Chen, 2018, Randomised Clinical Trial: Tong-Xie-Yao-Fang Granules versus Placebo for Patients with Diarrhoea-Predominant Irritable Bowel Syndrome, Aliment. Pharmacol. Ther., 48, 160, 10.1111/apt.14817 · DOI · Paper page
  12. Dai, 2018, Efficacy and Safety of Modified Tongxie Yaofang in Diarrhea-Predominant Irritable Bowel Syndrome Management: A Meta-Analysis of Randomized, Positive Medicine-Controlled Trials, PLoS ONE, 13, e0192319, 10.1371/journal.pone.0192319 · DOI
  13. Dale, 2019, Probiotics in Irritable Bowel Syndrome: An Up-To-Date Systematic Review, Nutrients, 11, 2048, 10.3390/nu11092048 · DOI
  14. Doshi, 2014, Economic burden of Irritable Bowel Syndrome with Constipation: a Retrospective Analysis of Health Care Costs in a Commercially Insured Population, J. Manag. Care. Spec. Pharm., 20, 382, 10.18553/jmcp.2014.20.4.382 · DOI
  15. Fan, 2017, Tongxie Formula Reduces Symptoms of Irritable Bowel Syndrome, Clin. Gastroenterol. Hepatol., 15, 1724, 10.1016/j.cgh.2017.06.026 · DOI
  16. Ford, 2017, Irritable Bowel Syndrome, N. Engl. J. Med., 376, 2566, 10.1056/NEJMra1607547 · DOI · Paper page
  17. Hu, 2009, The Alleviating Pain Effect of Aqueous Extract from Tong-Xie-Yao-Fang, on Experimental Visceral Hypersensitivity and its Mechanism, Biol. Pharm. Bull., 32, 1075, 10.1248/bpb.32.1075 · DOI
  18. Imberger, 2016, False-positive Findings in Cochrane Meta-Analyses with and without Application of Trial Sequential Analysis: an Empirical Review, BMJ Open, 6, e011890, 10.1136/bmjopen-2016-011890 · DOI
  19. Jin, 2019, Non-pharmacological Treatments for Irritable Bowel Syndrome: Study Protocol of an Umbrella Review of Systematic Review and Meta-Analyses, BMJ Open, 9, e027778, 10.1136/bmjopen-2018-027778 · DOI
  20. Kerckhove, 2017, Assessment of the Effectiveness and Safety of Ethosuximide in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome - IBSET: Protocol of a Randomised, Parallel, Controlled, Double-Blind and Multicentre Trial, BMJ Open, 7, e015380, 10.1136/bmjopen-2016-015380 · DOI
  21. Lembo, 2020, Abdominal Pain Response to Rifaximin in Patients with Irritable Bowel Syndrome with Diarrhea, Clin. Translational Gastroenterol., 11, e00144, 10.14309/ctg.0000000000000144 · DOI
  22. Leung, 2006, Treatment of Diarrhea-Predominant Irritable Bowel Syndrome with Traditional Chinese Herbal Medicine: a Randomized Placebo-Controlled Trial, Am. J. Gastroenterol., 101, 1574, 10.1111/j.1572-0241.2006.00576.x · DOI
  23. Li, 2015, A Systematic Review of Integrated Traditional Chinese and Western Medicine for Managing Irritable Bowel Syndrome, Am. J. Chin. Med., 43, 385, 10.1142/S0192415X15500251 · DOI
  24. Li, 2018, Tong-Xie-Yao-Fang Regulates 5-HT Level in Diarrhea Predominant Irritable Bowel Syndrome through Gut Microbiota Modulation, Front. Pharmacol., 9, 1110, 10.3389/fphar.2018.01110 · DOI
  25. Mearin, 2016, Clinical Practice Guideline: Irritable Bowel Syndrome with Constipation and Functional Constipation in the Adult, Rev. Esp. Enferm. Dig., 108, 332, 10.17235/reed.2016.4389/2016 · DOI
  26. Moayyedi, 2019, Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS), J. Can. Assoc. Gastroenterol., 2, 6, 10.1093/jcag/gwy071 · DOI · Paper page
  27. Pan, 2009, Effect of Tongxie Yaofang Granule in Treating Diarrhea-Predominate Irritable Bowel Syndrome, Chin. J. Integr. Med., 15, 216, 10.1007/s11655-009-0216-7 · DOI
  28. Passos, 2009, Adequate Relief in a Treatment Trial with IBS Patients: a Prospective Assessment, Am. J. Gastroenterol., 104, 912, 10.1038/ajg.2009.13 · DOI
  29. Sallon, 2002, A Novel Treatment for Constipation-Predominant Irritable Bowel Syndrome Using PadmaLax, a Tibetan Herbal Formula, Digestion, 65, 161, 10.1159/000064936 · DOI
  30. Shah, 2020, Trial Sequential Analysis: Adding a New Dimension to Meta‐analysis, Anaesthesia, 75, 15, 10.1111/anae.14705 · DOI
  31. Shi, 2008, Effectiveness and Safety of Herbal Medicines in the Treatment of Irritable Bowel Syndrome: A Systematic Review, World. J. Gasteroentrol., 14, 454, 10.3748/wjg.14.454 · DOI
  32. Shih, 2019, The Effect of Xiang-Sha-Liu-Jun-Zi Tang (XSLJZT) on Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial, J. Ethnopharmacology, 238, 111889, 10.1016/j.jep.2019.111889 · DOI · Paper page
  33. Simrén, 2017, Management of the Multiple Symptoms of Irritable Bowel Syndrome, Lancet Gastroenterol. Hepatol., 2, 112, 10.1016/S2468-1253(16)30116-9 · DOI
  34. Su, 2013, Curative Effect of Warming Kidney and Fortifying Spleen Recipe on Diarrhea-Predominant Irritable Bowel Syndrome, J. Traditional Chin. Med., 33, 615, 10.1016/s0254-6272(14)60030-3 · DOI
  35. Sultan, 2017, Irritable Bowel Syndrome, Ann. Intern. Med., 166, ITC81, 10.7326/AITC201706060 · DOI
  36. Tack, 2019, Economic burden of Moderate to Severe Irritable Bowel Syndrome with Constipation in Six European Countries, BMC Gastroenterol., 19, 69, 10.1186/s12876-019-0985-1 · DOI
  37. Tan, 2019, Herbal Medicine in the Treatment of Functional Gastrointestinal Disorders: A Systematic Review with Meta‐analysis, J. Gastroenterol. Hepatol., 35, 544, 10.1111/jgh.14905 · DOI
  38. Tang, 2018, Therapeutic Effect of Chang'an I Recipe on Irritable Bowel Syndrome with Diarrhea: A Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial, Chin. J. Integr. Med., 24, 645, 10.1007/s11655-016-2596-9 · DOI
  39. Tang, 2019, Post-marketing Re-evaluation of Tongxiening Granules in Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Multi-center, Randomized, Double-Blind, Double-Dummy and Positive Control Trial, Chin. J. Integr. Med., 25, 887, 10.1007/s11655-019-3030-x · DOI
  40. Wang, 2006, Tong-xie-ning, a Chinese Herbal Formula, in Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: a Prospective, Randomized, Double-Blind, Placebo-Controlled Trial, Chin. Med. J., 119, 2114, 10.1097/00029330-200612020-00015 · DOI
  41. Wang, 2018, Are Personalized Tongxie Formula Based on Diagnostic Analyses More Effective in Reducing IBS Symptoms?-A Randomized Controlled Trial, Complement. Therapies Med., 40, 95, 10.1016/j.ctim.2018.07.002 · DOI
  42. Yan, 2019, Acupuncture Plus Chinese Herbal Medicine for Irritable Bowel Syndrome with Diarrhea: A Systematic Review and Meta-Analysis, Evid Based. Complement. Altern. Med., 2019, 1, 10.1155/2019/7680963 · DOI
  43. Yang, 2015, Inhibitory Effect of TongXie-YaoFang Formula on Colonic Contraction in Rats, World. J. Gasteroentrol., 21, 2912, 10.3748/wjg.v21.i10.2912 · DOI
  44. Zhou, 2019, Clinical Effects and Safety of Tongxieyaofang on Diarrhea Predominant Irritable Bowel Syndrome: A Meta-Analysis of Randomized Trails, Evidence-Based Complement. Altern. Med., 2019, 1, 10.1155/2019/4893876 · DOI

Cited by

Metadata

Authors
Zheng, H., Jin, S., Shen, Y.-L., Peng, W.-Y., Ye, K., Tang, T.-C., Zhao, J., Chen, M., & Li, Z.-G.
Venue
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Published
2021-07-27
Volume
12
ISSN
1663-9812
DOI
10.3389/fphar.2021.694741
Cited by
19
References
3
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • Ministry of Science and Technology of the People’s Republic of China
  • Foundation for Innovative Research Groups of the National Natural Science Foundation of China

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.